Embolization agents are used to acutely stop the flow in a blood vessel or vascular territory by the means of mechanical occlusion. Embolization is a common procedure in interventional radiology. Traumatic injuries is the first common application of embolization techniques. Numerous embolic agents are available, each one with different properties and uses. The selection of agent depends on the clinical application; for example, trauma, vascular malformations, male infertility, tumors, and impotence. Embolization agents are classified into temporary agents and permanent agents depending on the period of time for which vascular occlusion is required.
Factors such as new product approval, growing prevalence of chronic diseases (such as cancer and vascular diseases), unmet needs, increasing health care expenditure, and rising number of road accidents leading to trauma would drive the embolization agents market in the next few years. The global health care industry expanded by 6.9% to reach US$ 1.68 Trn in 2016, with the industry in Asia Pacific registering a double-digit growth rate. Increasing number of clinical trials, rising number of pipeline products, and technological advancements are other factors augmenting the embolization agents market. Rapid evolution of the microcatheter technology has led to development of numerous embolic agents that are compatible with microcatheters. A growing number of embolic agents are designed specifically for use with the microcatheter technology. On the other hand, unfavorable reimbursement scenario and stringent government regulations are key factors that may hamper the global embolization agents market during the forecast period.
The embolization agents market has been segmented based on product, application, end-user, and geography. In terms of product, the market has been classified into permanent large-vessel occluders, permanent small-vessel occluders, temporary large-vessel occluders, and temporary small-vessel occluders. The permanent large-vessel occluders segment has been sub-classified into coils, balloons, amplatz vascular plugs, guidewires, silk suture material, porcine submucosa, and amplatz vascular obstruction devices. The permanent small-vessel occluders segment has been sub-divided into liquid sclerosants, liquid adhesives, ethiodol, thrombin, and ethylene–vinyl alcohol copolymer. The temporary large-vessel occluders segment has been sub-classified into gel foam sponges and autologous clots. The temporary small-vessel occlusions segment has been sub-divided into gel foam powder starch microspheres and fibrillated collagen. In terms of application, the embolization agents market has been classified into trauma, chemoembolization, tumors, and vascular malformations. In terms of end-user, the market has been segmented into hospitals, clinics, radiology centers, and ambulatory surgery centers.
Geographically, the global embolization agents market has been classified into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America dominates the global embolization agents market due to advanced health care infrastructure, high health care spending, and presence of a large number of cancer patients in the region. According to Cancer Statistics 2016, pancreatic cancer is expected to exceed breast cancer to become the third leading cause of cancer-related deaths in the U.S. Factors such as growing geriatric population and increasing number of surgical procedures make Europe the second-largest market for embolization agents. According to the Lancet Commission on Global Surgery, about 15,000 surgical procedures per 100,000 people are performed in the U.K. every year. The market in the Asia Pacific region is expected to expand at a higher rate during the forecast period, due to rising health care expenditure, favorable government initiatives, boom in the economy, developing health care infrastructure, rising prevalence of chronic diseases, growing awareness among people, and increasing R&D activities in the region. In Southeast Asia, the private health care expenditure is higher compared to the government expenditure.
Major players operating in the global embolization agents market are Boston Scientific Corporation, Stryker Corporation, Penumbra, Inc., Terumo Corporation, Medtronic Public Limited, Pfizer Inc., St. Jude Medical, LLC, and Cook Medical.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.